← Back to Search

Procedure

ActivSight for Colorectal Cancer

N/A
Waitlist Available
Research Sponsored by Activ Surgical
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 28 days
Awards & highlights
No Placebo-Only Group

Summary

This trial is a prospective, single-center, feasibility study with two sequential cohorts.

Who is the study for?
Adults (18+) undergoing specific laparoscopic surgeries like gastric sleeve, bypass, or cholecystectomy can join this trial. They must be able to understand and consent to the study's procedures and have no severe allergies or conditions that would exclude them.
What is being tested?
The ActivSightTM system is being tested for its ability to provide real-time visualization of blood flow during surgery. It aims to improve outcomes in intestinal anastomoses and bariatric surgery by comparing it with traditional methods.
What are the potential side effects?
Since ActivSightTM is a visual aid used during surgery rather than a drug, it may not have direct side effects. However, risks could include potential complications from incorrect surgical decisions based on the device's imaging.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~28 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 28 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Incidence of Adverse Events in 28 days following use of ActivSightTM
Latency of display of ActivSightTM.
Preparation time of ActivSightTM.
+4 more
Secondary study objectives
Biliary tract structure
Ability of ActivSightTM to display blood vessels.
Ability of ActivSightTM to display perfusion.

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: ActivSight GroupExperimental Treatment1 Intervention
Patients undergoing intestinal anastomoses (colorectal and bariatric) with ActivSight (n=52) Patients undergoing cholecystectomy with ActivSight (n=28)

Find a Location

Who is running the clinical trial?

University at BuffaloOTHER
135 Previous Clinical Trials
99,426 Total Patients Enrolled
Ohio State UniversityOTHER
871 Previous Clinical Trials
655,672 Total Patients Enrolled
Activ SurgicalLead Sponsor
3 Previous Clinical Trials
190 Total Patients Enrolled
The University of Texas Health Science Center, HoustonOTHER
957 Previous Clinical Trials
347,790 Total Patients Enrolled
University of Buffalo, Buffalo General HospitalUNKNOWN

Media Library

ActivSightTM (Procedure) Clinical Trial Eligibility Overview. Trial Name: NCT04633512 — N/A
Inflammatory Bowel Disease Research Study Groups: ActivSight Group
Inflammatory Bowel Disease Clinical Trial 2023: ActivSightTM Highlights & Side Effects. Trial Name: NCT04633512 — N/A
ActivSightTM (Procedure) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04633512 — N/A
Inflammatory Bowel Disease Patient Testimony for trial: Trial Name: NCT04633512 — N/A
~0 spots leftby Jan 2025